PMVP Insider Trading Activity and SEC Form 4 Filings
PMVP insider trading summary
No open-market insider purchases or sales of PMV Pharmaceuticals, Inc. (PMVP) have been reported on SEC Form 4 in the past 12 months.
Latest PMVP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 23, 2025 | Orbimed Advisors LLC | 10% Owner | Sell | $1.5M (1,000,000 @ $1.52) |
| Oct 23, 2025 | OrbiMed Capital GP V LLC | 10% Owner | Sell | $1.5M (1,000,000 @ $1.52) |
| Sep 10, 2025 | OrbiMed Capital GP V LLC | 10% Owner | Sell | $900K (500,000 @ $1.80) |
| Sep 10, 2025 | Orbimed Advisors LLC | 10% Owner | Sell | $900K (500,000 @ $1.80) |
| Jul 1, 2025 | Michael Carulli | Chief Financial Officer | Sell | $30K (28,249 @ $1.06) |
| Jul 1, 2025 | Robert Ticktin | General Counsel & COO | Sell | $25K (23,151 @ $1.06) |
| Jul 1, 2025 | David Henry Mack | President and CEO | Sell | $62K (58,411 @ $1.06) |
| Jul 1, 2025 | Deepika Jalota | Chief Development Officer | Sell | $35K (33,065 @ $1.06) |
| Sep 11, 2024 | Michael Carulli | Chief Financial Officer | Sell | $4K (2,891 @ $1.50) |
| Sep 11, 2024 | Deepika Jalota | Chief Development Officer | Sell | $11K (7,218 @ $1.50) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.